We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Excitement and Anticipation Surround the 2023 AACC Annual Scientific Meeting

By Jen A. Miller (AACC)
Posted on 07 Jul 2023
What’s it like to spend more than a year planning a scientific meeting for 20,000 people, and then be on the precipice of all that work being realized? More...
“Exciting,” said Amy Saenger, PhD, DABCC, FAACC, chair of AACC’s 12-member volunteer Annual Meeting Organizing Committee (AMOC). She expressed her anticipation as the meeting is set to return to pre-COVID-19 attendance numbers for the first time in years.

CLN spoke to her about the process of planning this year’s meeting and what attendees should expect.

WHAT ARE YOU LOOKING FORWARD TO THE MOST ABOUT THIS YEAR’S MEETING?
I’m mostly looking forward to having it be more like a normal meeting again, with almost everything in person. We expect attendance numbers to be back to or exceeding where they were prepandemic. I think we’re all looking forward to just getting back to ‘normal.’”

At the same time, we’re also offering virtual options for some of our sessions. We’ve improved the delivery of virtual content to ensure attendees can access the information they need. While our aim is to have people attend in person, we acknowledge that it may not work for everyone, so we want to ensure they have the opportunity to participate.

HOW HAVE CHANGES IN LAB MEDICINE AFFECTED THE CONTENT OF THE MEETING?
We've taken a targeted approach and conducted extensive outreach for our sessions, which has been incredibly successful. The content now showcases more innovative approaches to lab medicine, expanding beyond the traditional laboratory setting. For example, during the pandemic, clinical laboratories adapted their testing methods to serve homeless shelters, correctional facilities, and long-term care facilities. We’ll have sessions exploring these novel approaches and a broader focus on population health.

Clinical laboratorians have a lot of exciting things to share. We’re going to see a lot of cutting-edge science that’s coming out of lab medicine and clinical chemistry.

WHAT ELSE CAN ATTENDEES EXPECT THIS YEAR?
For this meeting, we’ve made a lot of changes to the format of the program that the AMOC is enthusiastic about. For example, we opened the poster sessions to all attendees, whether they’re expo only attendees or full conference attendees. We did that because we’re trying to increase the visibility of the posters and abstract presentations for everybody. It’s a good and significant change.

We also changed the topics of the posters and the abstracts to better align with our AACC divisions, and we are hoping to increase attendance there. If divisions decide to do poster walks again, they can more easily do so. This is a return to how we did things a few years ago, and we realized this worked well, so we made the change.

We also were able to work with the AACC’s journal Clinical Chemistry so that all our abstracts are indexed in the journal. I believe this also will boost visibility for all our authors, who put a lot of time and effort into doing these studies and presenting them.

Overall, attendees can expect to see a lot of excellent cutting-edge science and research in the field of laboratory medicine, and they should expect to have a lot of fruitful discussions and collaborations with their colleagues and other professionals in the field.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gastrointestinal Panel
Xpert® GI Panel
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.